Severe congenital neutropenia and pegfilgrastim

European Journal of Haematology

Volumn 82, Issue 1, 2009, Pages 75-76

  Lähteenmäki, Päivi M ^a   Jahnukainen, Kirsi ^a   Pelliniemi, Tarja Terttu ^a   Kainulainen, Leena ^a   Salmi, Toivo T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ELASTASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABSCESS; ADULT; ANTIBIOTIC PROPHYLAXIS; CASE REPORT; DISEASE SEVERITY; DRUG FORMULATION; EXPERIMENTAL THERAPY; FEVER; HUMAN; LETTER; MALE; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; TONGUE ABSCESS;

FILGRASTIM; HUMANS; MALE; NEUTROPENIA; TIME FACTORS; YOUNG ADULT;

EID: 57649231165     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01145.x     Document Type: Letter

References (9)

1. Carlsson G, Fasth A. Infantile genetic agranulocytosis, morbus Kostmann: presentation of six cases from the original "Kostmann family" and a review. Acta Paediatr 2001;90:757-64.
2. Zeidler C, Welte K. Kostmann syndrome and severe congenital neutropenia. Semin Hematol 2002;39:82-8.
3. Klein C, Grudzien M, Appaswamy G, et al. HAX1 de?ciency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007;39:86-92.
4. Carlsson G, Melin M, Dahl N, et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatr 2007;96:813-9.
5. Boxer LA, Stein S, Buckley D, Bolyard AA, Dale DC. Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. J Pediatr 2006;148:633-6.
6. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003;72:82-93.
7. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005;90:45-53.
8. Molineux G. The design and development of peg?lgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10:1235-44.
9. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006;107:4628-35.